Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed

Simply Wall St.05-17

Doximity, Inc. recently reported past fourth-quarter and full-year fiscal 2026 results, with revenue rising to US$145.37 million for the quarter and US$644.86 million for the year, but net income and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636009225?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-05-17 17:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636009225","market":"hk","top_or_hot":-1,"title":"Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>Doximity, Inc. recently reported past fourth-quarter and full-year fiscal 2026 results, with revenue rising to US$145.37 million for the quarter and US$644.86 million for the year, but net income and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/doximity-docs-is-down-270-after-softer-2027-outlook-and-high\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/doximity-docs-is-down-270-after-softer-2027-outlook-and-high><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doximity, Inc. recently reported past fourth-quarter and full-year fiscal 2026 results, with revenue rising to US$145.37 million for the quarter and US$644.86 million for the year, but net income and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/doximity-docs-is-down-270-after-softer-2027-outlook-and-high\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DOCS","symbol_name":"Doximity, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/doximity-docs-is-down-270-after-softer-2027-outlook-and-high","article_id":"2636009225","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/doximity-docs-is-down-270-after-softer-2027-outlook-and-high","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636009225","pubTimestamp":1779010900,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Doximity, Inc. recently reported past fourth-quarter and full-year fiscal 2026 results, with revenue rising to US$145.37 million for the quarter and US$644.86 million for the year, but net income and earnings per share declining versus the prior year as profitability came under pressure.\nAt the same time, Doximity announced a new integration that brings its Clinical AI Suite, including Scribe and Ask, into Aledade’s value-based care platform, underscoring how its AI tools are being embedded...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DOCS":"Doximity, Inc.","BK4543":"AI","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","AIPO":"Defiance AI and Power Infrastructure ETF","AI":"C3.ai, Inc.","BK4528":"SaaS概念","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4613":"AI应用软件","BK4023":"应用软件","ARTY":"ISHARES FUTURE AI & TECH ETF","AGIX":"通用人工智能 ETF-AGIX","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4167":"医疗保健技术"},"translate_title":"由于2027年前景疲软和人工智能支出增加，Doximity(DOCS)下跌27.0%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":1.5,"AIPO":1.5,"AIYY":0.6,"AGIX":1.5,"DOCS":1.5,"CHAT":1.5,"AI":0.9},"content_text":"Doximity, Inc. recently reported past fourth-quarter and full-year fiscal 2026 results, with revenue rising to US$145.37 million for the quarter and US$644.86 million for the year, but net income and earnings per share declining versus the prior year as profitability came under pressure. At the same time, Doximity announced a new integration that brings its Clinical AI Suite, including Scribe and Ask, into Aledade’s value-based care platform, underscoring how its AI tools are being embedded directly into physicians’ everyday workflows. We’ll now examine how softer fiscal 2027 guidance, driven partly by higher AI-related spending, reshapes Doximity’s previously optimistic investment narrative. Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementDoximity Investment Narrative RecapTo own Doximity, you need to believe its physician network and AI workflow tools can stay central to how U.S. clinicians work, even as growth slows and pharma ad budgets wobble. The key short term catalyst is whether heavier AI spending begins to translate into clearer revenue opportunities, while the biggest current risk is margin pressure from that same AI investment combined with softer pharma marketing demand. The latest results and fiscal 2027 guidance materially sharpen both of those concerns. Against that backdrop, the new Aledade integration looks especially important. Embedding Scribe and Ask directly into Aledade Assist’s value based care platform reinforces Doximity’s role inside everyday clinical workflows, which matters if investors are watching for evidence that AI tools can deepen stickiness with health systems and prescribers, even while near term profitability and growth guidance disappoint. But beneath the appeal of AI tools and workflow integrations, investors should also be aware that ... Read the full narrative on Doximity (it's free!)Doximity's narrative projects $782.1 million revenue and $249.4 million earnings by 2029.Uncover how Doximity's forecasts yield a $37.77 fair value, a 99% upside to its current price.Exploring Other PerspectivesDOCS 1-Year Stock Price Chart Some of the lowest estimate analysts were already cautious, assuming only about 7 percent annual revenue growth to roughly US$784 million and shrinking margins, and this latest guidance plus AI spending debate could either validate that view or prompt a rethink, so it is worth comparing these more pessimistic expectations with your own assumptions before deciding how you feel about Doximity’s next chapter.Explore 5 other fair value estimates on Doximity - why the stock might be worth just $25.00!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.Looking For Alternative Opportunities?Every day counts. These free picks are already gaining attention. See them before the crowd does:AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636009225","isCrawlerRequest":true}